Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2016 1
2017 4
2018 8
2019 4
2020 4
2021 6
2022 13
2023 17
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Endoscopic Ultrasound-guided Radiofrequency Ablation Versus Surgical Resection for Treatment of Pancreatic Insulinoma.
Crinò SF, Napoleon B, Facciorusso A, Lakhtakia S, Borbath I, Caillol F, Do-Cong Pham K, Rizzatti G, Forti E, Palazzo L, Belle A, Vilmann P, van Laethem JL, Mohamadnejad M, Godat S, Hindryckx P, Benson A, Tacelli M, De Nucci G, Binda C, Kovacevic B, Jacob H, Partelli S, Falconi M, Salvia R, Landoni L; ERASING study collaborators; Larghi A. Crinò SF, et al. Clin Gastroenterol Hepatol. 2023 Oct;21(11):2834-2843.e2. doi: 10.1016/j.cgh.2023.02.022. Epub 2023 Mar 4. Clin Gastroenterol Hepatol. 2023. PMID: 36871765
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study.
Nesti C, Bräutigam K, Benavent M, Bernal L, Boharoon H, Botling J, Bouroumeau A, Brcic I, Brunner M, Cadiot G, Camara M, Christ E, Clerici T, Clift AK, Clouston H, Cobianchi L, Ćwikła JB, Daskalakis K, Frilling A, Garcia-Carbonero R, Grozinsky-Glasberg S, Hernando J, Hervieu V, Hofland J, Holmager P, Inzani F, Jann H, Jimenez-Fonseca P, Kaçmaz E, Kaemmerer D, Kaltsas G, Klimacek B, Knigge U, Kolasińska-Ćwikła A, Kolb W, Kos-Kudła B, Kunze CA, Landolfi S, La Rosa S, López CL, Lorenz K, Matter M, Mazal P, Mestre-Alagarda C, Del Burgo PM, van Dijkum EJMN, Oleinikov K, Orci LA, Panzuto F, Pavel M, Perrier M, Reims HM, Rindi G, Rinke A, Rinzivillo M, Sagaert X, Satiroglu I, Selberherr A, Siebenhüner AR, Tesselaar MET, Thalhammer MJ, Thiis-Evensen E, Toumpanakis C, Vandamme T, van den Berg JG, Vanoli A, van Velthuysen MF, Verslype C, Vorburger SA, Lugli A, Ramage J, Zwahlen M, Perren A, Kaderli RM. Nesti C, et al. Among authors: perrier m. Lancet Oncol. 2023 Feb;24(2):187-194. doi: 10.1016/S1470-2045(22)00750-1. Epub 2023 Jan 11. Lancet Oncol. 2023. PMID: 36640790
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
Walter T, Lievre A, Coriat R, Malka D, Elhajbi F, Di Fiore F, Hentic O, Smith D, Hautefeuille V, Roquin G, Perrier M, Dahan L, Granger V, Sobhani I, Mineur L, Niccoli P, Assenat E, Scoazec JY, Le Malicot K, Lepage C, Lombard-Bohas C. Walter T, et al. Among authors: perrier m. Lancet Oncol. 2023 Mar;24(3):297-306. doi: 10.1016/S1470-2045(23)00001-3. Epub 2023 Feb 2. Lancet Oncol. 2023. PMID: 36739879 Clinical Trial.
FOLFOX-bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors.
Lacombe C, Perrier M, Hentic O, Brixi H, De Rycke O, Cros J, Rebours V, Cadiot G, Ruszniewski P, de Mestier L. Lacombe C, et al. Among authors: perrier m. J Neuroendocrinol. 2023 Jan;35(1):e13227. doi: 10.1111/jne.13227. Epub 2023 Jan 4. J Neuroendocrinol. 2023. PMID: 36599808 Free PMC article.
Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors.
De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C, Coriat R, Cadiot G, Couvelard A, Ruszniewski P, Cros J, de Mestier L. De Rycke O, et al. Among authors: perrier m. Endocr Relat Cancer. 2021 Jun 11;28(7):457-466. doi: 10.1530/ERC-21-0034. Endocr Relat Cancer. 2021. PMID: 33979778
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
Hadoux J, Walter T, Kanaan C, Hescot S, Hautefeuille V, Perrier M, Tauveron I, Laboureau S, Do Cao C, Petorin C, Blanchet O, Faron M, Leteurtre E, Rousselet MC, Joubert Zakeyh J, Marchal A, Chatelain D, Beaulaton C, Hervieu V, Lombard-Bohas C, Ducreux M, Scoazec JY, Baudin E; Groupe d’Etude des Tumeurs Endocrines (GTE); ENDOCAN-RENATEN network. Hadoux J, et al. Among authors: perrier m. Endocr Relat Cancer. 2022 Aug 17;29(10):569-580. doi: 10.1530/ERC-22-0102. Print 2022 Oct 1. Endocr Relat Cancer. 2022. PMID: 35920609
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
de Mestier L, Lamarca A, Hernando J, Zandee W, Alonso-Gordoa T, Perrier M, Walenkamp AM, Chakrabarty B, Landolfi S, Van Velthuysen MF, Kats-Ugurlu G, Caminoa A, Ronot M, Manoharan P, Garcia-Alvarez A, Brabander T, García Gómez-Muriel MI, Cadiot G, Couvelard A, Capdevila J, Pavel ME, Cros J. de Mestier L, et al. Among authors: perrier m. Endocr Relat Cancer. 2021 Jun 23;28(8):549-561. doi: 10.1530/ERC-21-0109. Endocr Relat Cancer. 2021. PMID: 34061764
Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability.
Boyer C, Sefrioui D, Cohen R, Chautard R, Perrier M, Lebrun H, Goujon G, Hautefeuille V, Dior M, Walter T, Mary F, Manfredi S, Caroli-Bosc FX, Cervantes B, Coriat R, Deluche E, Zaanan A, Olivier R, Bouché O, Piessen G, Lecomte T, Louvet C, Michel P, Aparicio T, André T, Taieb J, Randrian V, Tougeron D. Boyer C, et al. Among authors: perrier m. Dig Liver Dis. 2023 Jan;55(1):123-130. doi: 10.1016/j.dld.2022.03.011. Epub 2022 Apr 6. Dig Liver Dis. 2023. PMID: 35397988
56 results